ASNDAscendis Pharma A/S
Price
+16%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, growing in the filings, the market undecided.
We are a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we develop TransCon-based therapies that demonstrate best-in-class potential to address unmet medical needs. Our portfolio of Endocrinology Rare Disease approved products and product candidates addresses hypoparathyroidism and growth disorders.
In the company’s own words · 20-F filed Feb 11, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Ascendis Pharma A/S (ASND) reported revenue of €248M in Q4 2025 (quarter ended Dec 31, 2025), up 42% from the same quarter a year earlier. That came with a gross margin of 90% and net loss of €34M. For the full year FY2025, revenue was €720M (+98% year on year) and net income −€228M.
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.